Drugs / DS-8273a
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02991196 | Dec 2016 → Sep 2017 | colorectal neoplasm | Daiichi Sankyo | Terminated | No outcome recorded |
| Phase 1 | NCT02983006 | Oct 2016 → Dec 2019 | melanoma | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT02076451 | Feb 2014 → Dec 2015 | lymphoma | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-8273a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02991196 ↗ |
| Known as | DS-8273 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594356 ↗ |
| Modality | Monoclonal antibody | “TRAIL-R2 (DR5) Antibody DS-8273a” NCT02991196 ↗ |
| Route | Intravenous | “administered as an intravenous (IV) solution” NCT02076451 ↗ |